1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Bausch Health Companies Inc.
  6. Summary
    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
Delayed Toronto Stock Exchange  -  04:00 2022-08-12 pm EDT
7.690 CAD   -2.90%
08/11Toronto market closes up at 2-month high as oil prices rally
RE
08/11Bausch Health Says it Will Appeal Xifaxan Patent Decision; Shares Rise
MT
08/11TSX extends gains on strong Canada Goose earnings
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
08/08/2022 08/09/2022 08/10/2022 08/11/2022 08/12/2022 Date
7.5(c) 6.7(c) 7.22(c) 7.92(c) 7.69(c) Last
1 340 461 2 117 686 1 642 514 1 559 919 1 255 169 Volume
+3.59% -10.67% +7.76% +9.70% -2.90% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 8 197 M - -
Net income 2022 -118 M - -
Net Debt 2022 17 096 M - -
P/E ratio 2022 -18,5x
Yield 2022 -
Sales 2023 8 451 M - -
Net income 2023 297 M - -
Net Debt 2023 18 073 M - -
P/E ratio 2023 7,42x
Yield 2023 -
Capitalization 2 174 M 2 174 M -
EV / Sales 2022 2,35x
EV / Sales 2023 2,40x
Nbr of Employees 19 600
Free-Float 95,6%
More Financials
Company
Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company develops, manufactures, and markets, primarily in the therapeutic areas of eye health, gastroenterology (GI), and dermatology, a range of branded, generic and branded generic pharmaceuticals, over the counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Ratings of Bausch Health Companies Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BAUSCH HEALTH COMPANIES INC.
08/11Toronto market closes up at 2-month high as oil prices rally
RE
08/11Bausch Health Says it Will Appeal Xifaxan Patent Decision; Shares Rise
MT
08/11TSX extends gains on strong Canada Goose earnings
RE
08/11Bausch Health Companies Inc. - Salix Supports CMS Announcement of First ICD-10 Code for..
AQ
08/10MT NEWSWIRES CANADA OVERNIGHT STOCKS : Avino Silver & Gold; Fortuna; Pan American Silver C..
MT
08/10BAUSCH HEALTH COMPANY BRIEF : To Appeal XIFAXAN Patent Decision to U.S. Court of Appeals f..
MT
08/10Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Feder..
PR
08/10Stifel Nicolaus Adjusts Price Target for Bausch Health Companies to $15 From $40, Maint..
MT
08/10BMO Capital Reviews Bausch Health's Q2
MT
08/10RBC Capital Reviews Bausch Health's Q2, Trims Target to US$4.50
MT
08/10BMO Capital Lowers Bausch Health Companies' Price Target to $8 From $15, Maintains Mark..
MT
08/10Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
AQ
08/10Salix Supports Bausch Health Companies Inc.'s First ICD-10 Code for Hepatic Encephalopa..
CI
08/09BAUSCH HEALTH COMPANIES INC. Management's Discussion and Analysis of Financial Conditi..
AQ
08/09Toronto Stocks Slide; Bausch Health Tumbles on Lower Performance Outlook for 2022
DJ
More news
News in other languages on BAUSCH HEALTH COMPANIES INC.
08/11Bausch Health déclare qu'elle fera appel de la décision sur le brevet du Xifaxan ; les ..
08/10Salix soutient le premier code CIM-10 pour l'encéphalopathie hépatique de Bausch Health..
08/09Bausch Health affiche un chiffre d'affaires de 1,967 milliard de dollars US au 2e trime..
08/09Bausch Health Companies Inc. annonce ses résultats pour le deuxième trimestre et le sem..
08/09Earnings Flash (BHC.TO) LES COMPAGNIES DE SANTÉ BAUSCH affichent un chiffre d'affaires ..
More news
Analyst Recommendations on BAUSCH HEALTH COMPANIES INC.
More recommendations
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 6,01 $
Average target price 13,25 $
Spread / Average Target 120%
EPS Revisions
Managers and Directors
Thomas J. Appio Chief Executive Officer & Director
John Alfred Paulson Chairman
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
Thomas Warren Ross Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BAUSCH HEALTH COMPANIES INC.-77.99%2 174
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131